PKM and ovarian cancer: Min Tian et al. (2021) found that Anexelekto (AXL) inhibited the activity of PKM2 and promoted aerobic glycolysis by phosphorylating PKM2, which was relevant to cisplatin-mediated drug resistance in ovarian cancer [31].